# A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma

Source: https://onco.cc/trials/nct07518186/  
OnCo record `nct07518186` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial testing JNJ-79635322 in multiple myeloma, now recruiting.

## Summary

A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma is a phase 3 interventional study registered as NCT07518186, led by Janssen Research & Development, and recruiting on the registry. Official title: A Phase 3 Randomised Study Comparing JNJ-79635322 Versus Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma After 1 to 3 Prior Lines of Therapy, Including an Anti-CD38 Antibody and Lenalidomide. Planned enrolment is 700 participants (estimated). The study started in 2026-05-31 and primary completion is expected in 2029-04-29. No results have been posted on ClinicalTrials.gov.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-11
- Also known as: TRIlogy-5
- Tags: ctgov-ingest
- Registry id: NCT07518186
- Phase: 3
- Setting: A Phase 3 Randomized Study Comparing JNJ-79635322 Versus Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma After 1 to 3 Prior Lines of Therapy, Including an Anti-CD38 Antibody and Lenalidomide
- Sponsor: Janssen Research & Development
- Enrolled: 700

## Sources

- ClinicalTrials.gov NCT07518186: https://clinicaltrials.gov/study/NCT07518186

## Connected records

- cancers: [Multiple myeloma](https://onco.cc/cancers/multiple-myeloma/), [Relapsed or refractory multiple myeloma](https://onco.cc/cancers/myeloma-relapsed-refractory/)
- drugs: [JNJ-79635322](https://onco.cc/drugs/jnj-79635322/)
- companies: [Johnson & Johnson](https://onco.cc/companies/johnson-johnson/)

---
JSON: https://onco.cc/api/v1/entities/nct07518186.json